Sign in →

Test Code FISHQ FISH, MDS/Myeloid Panel, -5/5q-, -7/7q-, +8, 20q-

Specimen Required

5 mL whole blood , 3 mL bone marrow collected in sodium heparin (green-top) tube

Specimen Minimum Volume

1 mL whole blood or bone marrow

Specimen Stability

Room temperature: See instructions Refrigerated: See instructins Frozen: See instructions

Day(s) and Time(s) Performed

Set up: Sun-Fri; Report available: 7 days

Method Name

Fluorescence in situ Hybridization (FISH)


Methodology: Four probe sets associated with myelodysplastic syndrome (MDS) are included in this panel: 5/5q, 7/7q, +8, 20q-. 100-300 interphase nuclei are scored for each probe set to detect gain, loss, or rearrangements of the probe regions.

Collection Container / Tube

Preferred: sodium heparin (green top) tube
Other Acceptable Container: Sodium heparin (royal blue-top) tube, or sodium heparin lead-free (tan-top) tube

Transport / Storage Conditions

Room temperature

Special Instructions

Clinical history/reason for referral is required with test order. Prior therapy and transplant history should be provided.

Submit 3-5 mL whole blood or 1-3 mL bone marrow collected in a sodium heparin tube.
Specimen viability decreases during transit. Send specimen to testing laboratory for viability determination. Do not freeze. Do not reject.

Reference Values

See Laboratory Report

CPT Codes

88275 (x3), 88271 (x6)

Clinical Reference

Prognostic investigation in patients with myelodysplasia or other myeloid malignancies. Among the patients with myelodysplastic syndromes (MDS), 45-50% have a least one chromosome rearrangement, the most common of which can be detected using this fluorescence in situ hydridization (FISH) panel (-5/5q-,-7/7q-,+8,20q-). This panel of FISH probes can increase the detection rate of chromosome abnormalities at diagnosis and aid in follow-up testing for clinically significant chromosome abnormalities in MDS. The identification of the specific chromosome regions involved in a patient’s disease may play a significant role in treatment decisions as MDS targeted therapies are developed.